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Test-retest reliability, concurrent validity and correlates of the two-minute walk test in 
outpatients with psychosis 
Davy Vancampfort, Samuel Kimbowa, David Basangwa, Lee Smith, Brendon Stubbs, Tine Van 
Damme, Marc De Hert, James Mugisha 
 
Abstract  
The aim of this study was to investigate the test-retest reliability of the 2-minute walk test (2MWT) and 
the concurrent validity with the 6-minute walk test (6MWT) in outpatients with psychosis. We also 
explored whether there was a practice effect, determined minimal detectable changes (MDC) and 
assessed which factors are associated with the 2MWT performance. Fifty outpatients [22 women; 33.5 
(14.3) years] performed the 2MWT twice and the 6MWT once and completed the Simple Physical 
Activity Questionnaire (SIMPAQ) and Brief Symptoms Inventory -18. The median (interquartile) 2MWT 
score on the first and second test were 128.0 (44.0) meters and 128.0 (31.5) meters, without significant 
difference between the two trials. The intraclass coefficient was 0.94 (95% confidence interval=0.91-
0.97). The significant Spearman Rho correlation between the second 2MWT and the 6MWT was 0.69. 
The MDC was 22 meters for men and 21 meters for women. There was no evidence for a practice effect. 
Variability in SIMPAQ sedentary, exercise, incidental physical activity and leg pain following the test 
explained 54.6% of the variance in 2MWT score. The current study demonstrates that the 2MWT is a 
reliable, valid and clinically feasible tool for assessing and evaluating the functional exercise capacity in 
outpatients with psychosis. 
 















Despite the recognition that psychosis imposes worldwide a tremendous mental and physical health 
burden (Morgan et al., 2014; Stubbs et al., 2016a), lifestyle interventions designed to address medical 
co-morbidities are still scarcely used in treatment programs (Vancampfort et al., 2019). To the best of 
our knowledge, currently only a few screening, monitoring and treatment guidelines refer to the role of 
physical activity, and its structured form exercise, in people with psychosis and no single guideline has 
an adequate focus on the importance of physical fitness testing within this population (Brendon et al., 
2018; Mitchell et al., 2012; Vancampfort et al., 2012a; Vancampfort et al., 2015a). This is surprising as 
physical fitness is not only related to physical health but is also strongly associated with mental health 
outcomes. For example, a higher physical fitness is associated with a lower risk for psychotic episodes 
(Kunutsor et al., 2018). Therefore, fitness testing  is not only useful for  guiding exercise prescriptions, 
it also can be an important screening tool for assessing those at a higher risk for relapse (American 
College of Sports Medicine, 2013; Vancampfort et al., 2015a). 
 Previous research demonstrated that the 6 minute walk test (6MWT) is a reliable and valid test that 
can be used in clinical practice (Bernard et al., 2014). However, the available evidence has not been 
translated yet in changes in clinical practice and the 6MWT is not used in standard care packages in 
most parts of the world (Bernard et al., 2014). One of the reasons why the 6MWT is underutilized in 
clinical settings is the limited time of the existing work staff (Mugisha et al., 2019). Therefore, even briefer 
fitness tests than the 6MWT might be more useful and used more in busy clinical settings. The 2-minute 
walk test (2MWT) is such a short test. The 2MWT is a safe, easy to administer and inexpensive physical 
fitness test. It evaluates in two minutes the global and integrated responses of the cardiovascular, 
peripheral circulation and neuromuscular systems involved during exercise (Bohannon et al., 2014). It 
assesses the sub-maximal level of physical fitness (ATS, 2002). Because most activities of daily living 
are performed at sub-maximal levels of exertion, the 2MWT may better reflect the functional capacity of 
a person or the capacity to perform daily physical activities (i.e. functional exercise capacity), which is a 
part of a person’s overall physical fitness (Bohannon et al., 2014). Despite the potential clinical value, 
the reproducibility and validity of the 2MWT has not been assessed among patients with psychosis. 
Previous research in other clinical populations such as people with multiple sclerosis (Scalzitti et al., 
2018) and people with dementia (Chan and Pin, 2019), demonstrated good construct and discriminant 
validity of the 2MWT, providing an efficient and practical alternative to the 6MWT. 
The primary aim of the present study therefore was to investigate the test-retest reliability of the 
2MWT and the concurrent validity with the 6MWT in outpatients with psychosis. Secondary aims were: 
(a) to explore whether there was a practice effect with repeated testing, (b) to determine limits for the 
smallest difference that indicated a real change, and (c) to assess clinical and demographic 






















Over a 5-month period, all outpatients with a DSM 5 diagnosis of psychosis (American Psychiatric 
Association) of Butabika National Referral Hospital in Uganda (Kampala) were invited to participate. 
Participants were excluded if they had significant cardiovascular, neuromuscular and endocrine 
disorders, which, according to the American College of Sports Medicine (ACSM, 2013), might prevent 
safe participation in the study. Participants were requested to refrain from eating a heavy meal, drinking 
tea/coffee or smoking during a two-hour period prior to the tests in order to avoid interaction with the 
test performance. All outpatients performed the first 2MWT and afterwards completed the Simple 
Physical Activity Questionnaire (SIMPAQ) (Rosenbaum and Ward, 2016), and the Brief Symptoms 
Inventory -18 (BSI-18) (Derogatis, 2001). Following completion of the questionnaires, they performed a 
6 minute walk test (ATS, 2002) after a two hours rest period to that fatigue or any physical pain would 
interfere. The second 2MWT was repeated a day later on the same hour of the day and if not possible 
for practical reasons within two days to avoid that fatigue or any physical pain would interfere with the 
second test performance. The study procedure was approved by the ethical committee of Mengo 
Hospital, which covers also the Butabika National Referral Hospital. The research was conducted in 
accordance with the principles of the Declaration of Helsinki. All participants gave their informed written 
consent.  
 
2.2. Sample size analysis 
An a-priori sample size calculation was conducted following recommendations for reliability analyses 
(Walter et al., 1998). With a more than acceptable intraclass correlation coefficient (ICC) of 0.80, and 
alpha of 0.05 and power of 0.8 (β=0.2) it was established that 46 participants were required in the final 
analysis (Walter et al., 1998). It was anticipated that approximately 10 to 20% of patients approached 
would be excluded, and 10% would refuse for motivational reasons. Therefore, a pre-specified sample 
size of 55 to 60 participants was utilized to account for these factors in order to ensure the final analysis 




Test-retest 2MWT and concurrent validity with the 6MWT 
A test-retest design was used to test the reproducibility and validity of the 2MWT. The test was 
performed according to the American Thoracic Society guidelines in an indoor corridor with lack of 
external stimuli (ATS, 2002). Two cones 25 m apart indicated the length of the walkway in a quite 
administration building of the hospital. Participants were instructed to walk back and forth around the 
cones during 2 or 6 minutes, without running or jogging. Resting was allowed if necessary, but walking 
was to be resumed as soon as the participants were able to do so. The protocol (see Appendix) stated 
that the testing was to be interrupted if threatening symptoms appeared, including (a) chest pain, (b) 
intolerable dyspnea, (c) leg cramps, (d) staggering, (e) diaphoresis, and (f) pale or ashen appearance 
(ATS, 2002; Bohannon et al., 2015). Standardised encouragements were provided in Luganda or 
English (if not Luganda – speaking) at recommended intervals. The total distance walked in 2 or 6 
minutes was recorded to the nearest decimetre. All supervisions and measurements of the walk test 
were performed by the same trained occupational therapist with 3 years of expertise in working with 
people with psychosis. Prior to the first 2MWT, participants were asked for conditions that might interfere 
with their functional exercise capacity. They were asked whether they had known hip problems or pain, 
foot or ankle static problems or pain in the 30 days before the test. Moreover, they were asked to state 
if they suffered at least sometimes from knee or lower back pain in the past 3 months. Directly after the 
first test, patients were also asked to report any physical complaints or discomfort.  
 
SIMPAQ (Rosenbaum and Ward, 2016) 
The 5-item Luganda (or English) version  of the SIMPAQ requires people being interviewed to account 
for time spent in bed overnight (box 1), time sedentary, including napping (box 2), time spent walking 
(box 3), time spent exercising (box 4) and time engaged in incidental activity (e.g. household chores) 
(box 5), averaged over the past seven-day period. The sum of the hours recorded in the five SIMPAQ 
boxes should add to approximately 24-hours, providing interviewers with an opportunity to clarify with 
participants if significant under or over-reporting has occurred (e.g. total of <18 hours or >30 hours 
accounted for). We used the time spent sedentary, in incidental physical activity and in moderate to 
vigorous physical activity (MVPA). For an estimated of total self-reported MVPA time, time spent walking 
(box 3) and exercising (box 4) were combined to provide total MVPA (hours per week). 
 
BSI-18 (Derogatis, 2001) 
Symptoms were assessed with the Luganda (or English) version of the BSI-18 (Derogatis, 2001). The 
BSI-18 (Derogatis, 2001) is a self-reported screening inventory designed to assess participants’ level of 
psychological distress on three dimensions: somatization, depression, and anxiety. The 18 items are 
divided equally across the three dimensions and were presented with the standard instructions asking 
participants to rate how much they have been “distressed or bothered” in the past 7 days, including 
today, by the given symptom, using a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely). 
Each item contributes to only one subscale, which is scored by summing the scores on each of the six 




Participants were asked whether they smoked or not, and if so, how many cigarettes they smoke per 
day on average. 
 
Anthropometric measurements 
Body weight was measured in light clothing to the nearest 0.1kg using a SECA beam balance scale, 
and height to the nearest 0.1cm using a wall-mounted stadiometer.  
 
Medication use 
Psychotropic medication use was retrieved from the medical files for all included participants.  
 
Statistical analysis  
Continuous data were assessed for normality using the Shapiro-Wilk test. The only normally distributed 
variable was BMI which was presented as mean ± standard deviation (SD). The other, non-normally 
distributed variables were expressed as medians (interquartile range). The ICC between the two 2MWTs 
using a one-way random single measures intraclass correlation analysis and its associated 95% CI were 
calculated to objectively assess reliability between two 2MWTs. The concurrent validity of the second 
2MWT with the 6MWT was assessed via a Spearman Rho correlation. To assess whether there was a 
practice effect with repeated testing, the three following methods were used; (a) an ICC of less than 
0.75 for the two 2MWTs, (b) a statistically significant improvement in the 2MWT scores between two 
trials evaluated with the Wilcoxon matched pairs hypothesis test comparing test and retest 
measurements, and (c) a Spearman Rho correlation of less than 0.75 between the two 2MWTs. 
Because previous studies did not operationally define practice effects and no single method of 
evaluation has been identified as superior to the others, the present study considers in parallel with a 
previous studies (Vancampfort et al., 2015b; Vancampfort et al., 2015c) that a practice effect was to be 
present only if all three criteria were fulfilled. The minimal detectable change (MDC) for both men and 
women is calculated by multiplying the standard error of measurement (SEM) by 1.96 to correspond to 
the 95% CI and the square root of 2 to adjust for sampling from 2 different measurements. The SEM is 
estimated as the pooled standard deviation (SD) of pre-test and post-test assessments multiplied by the 
square root of (1-ICC) (de Vet et al., 2006). The SEM quantifies the within-subject variability and takes 
the amount of measurement error into consideration. MDC95 means one can be 95% confident that a 
change score equal or exceeding this threshold is true and reliable and not just a measurement error 
(Portney and Watkins, 2000). Correlates with the second 2MWT were assessed with a Spearman Rho 
or Pearson correlation coefficient when differences in 2MWT scores between two groups (e.g. men 
versus women) where assessed with a student-t or Mann Whitney U test when appropriate. A backward 
stepwise multivariable regression analysis was performed to evaluate independent variables explaining 
the variance in the 2MWT performance. To prevent overfitting of the models, only variables significant 
(P<0.05) in univariate analyses were entered into the final model. To test for multicollinearity, a variance 
inflation factor was computed for each independent variable in the model. Values above 3 were used to 
indicate a multicollinearity problem in the model. The difference in age between men and women was 
explored with a Mann Whitney U test. A priori, a two sided level of significance was set at P<0.05. 










A total of 55 outpatients with psychosis were initially screened. Three people were excluded as a 
consequence of a cardiovascular or neuromuscular disorder that may have  prevented safe participation. 
Of the 52 eligible people with psychosis, two declined to participate (i.e., were not interested). In total, 
50 [22♀, median (interquartile range) age= 33.5 (14.3)] participants were included in the final analysis.  
There was no significant  difference in age between men and women (P= 0.055). All participants were 
Ugandan natives and only one patient (2%) of the participants smoked, and this five cigarettes per day. 
In total, 43 patients had a diagnosis of brief psychotic disorder, six schizophrenia, and one bipolar 
disorder with psychotic features. An overview of the medication use of the entire sample is presented in 
Table 1. The majority (72%) was on mono-pharmacotherapy. No patient was drugs-naïve. Patients were 
more often treated with first generation antipsychotics (60% of the participants) with chlorpromazine the 
most used one (18%). Twenty percent (n=10) was treated with a second-generation antipsychotic with 
olanzapine the most commonly used one (12%). Other patients were treated with either antidepressants 
or mood stabilizers, i.e. 10% received an antidepressant, and 16% a mood stabilizer. No participants 
were treated with somatic medication. Before the first 2MWT, 8% (n=4) of patients with psychosis 
reported suffering from hip pain and 18% (n=9) from feet or ankle static problems or pain. Ten patients 
(20%) complained of at least sometimes having pain in their knees during the previous three months 
and 42% (n=21) reported experiencing lower back pain at least sometimes during the previous three 
months. Following the 2MWT, patients with psychosis experienced most often leg pain (20%, n=10), 
followed by dyspnea (12%, n=6). Other demographical and clinical variables are presented in Table 2. 
Insert Table 1 about here 
 
Reliability and concurrent validity with the 6MWT of the 2MWT 
The median (interquartile) 2MWT score on the first and second test were 128.0 (44.0) meters and 128.0 
(31.5) meters, respectively, without significant difference between the two trials (P=0.91). In men this 
was 137.0 (46.5) meters and 137.0 (47.2) meters (P=0.91) and in women 123.5 (34) meters and 123 
(30) meters (P=0.91), respectively. Analyses of reproducibility of the 2MWT showed that the ICC was 
0.94 with a 95% confidence interval of 0.91 to 0.97. In men, this was 0.94 (95% CI = 0.88 – 0.97) and 
in women 0.94 (95% CI = 0.86 – 0.97). The median (interquartile) distance achieved on the 6MWT was 
389.5 (83.5) meters, in men this was 405.0 (131.7) meters, and in women 362.0 (79.5) meters. There 
was a significant correlation with the 6MWT. The Spearman Rho correlation between the second 2MWT 
and the 6MWT was 0.69 (P<0.001), in men this was 0.70 (P<0.001), and in women 0.64 (P=0.001). 
 
Minimal detectable changes of the 2MWT 
The MDC95 in the present study was 22 meters for men and 21 meters for women. 
 
Determination of a practice effect 
There was no practice effect since the ICC was more than 0.75 for the two 2MWTs, the 2MWT scores 
between two trials was not significant (P=0.91) and the Spearman Rho between the two 2MWTs was 
less than 0.75 and this for both men and women.  
 
Factors affecting the second 2MWT 
Spearman Rho or Pearson correlations with the MWT are presented in Table 2. The 2MWT was 
significantly (P<0.05) associated with the SIMPAQ sedentary, walking, exercise and incidental physical 
activity scores. Patients who experienced any locomotor problem before the test walked significantly 
less, i.e. 121.5 (39.0) versus 136.0 (43.2) meters (P=0.002). Also those who experienced leg pain 
following the test walked significantly less distance on the 2MWT [112.0 (35.0) versus 136.0 (29.5) 
meters, P<0.001. All significant (P<0.05) continuous (SIMPAQ sedentary, walking, exercise and 
incidental physical activity) and dichotomous (i.e. gender, presence of locomotor pain before the test 
and leg pain following the test) correlates of the 2MWT in univariate analyses were included in the 
backward stepwise regression analysis. SIMPAQ walking had a variance inflation factor of more than 3, 
and was removed. SIMPAQ sedentary, SIMPAQ exercise, SIMPAQ incidental physical activity and leg 
pain following the test remained significantly associated with the 2MWT distance (see Table 3). The final 
model explained 54.6% of the variance in the distance walked on the 2MWT. 







To the best of our knowledge, the current study is the first to explore the test-retest reliability and 
concurrent validity of the 2MWT in people with psychosis. Our data show that the 2MWT has an excellent 
test-retest reliability with an ICC of 0.94 (95% CI = 0.91 - 0.97) and an excellent concurrent validity with 
the 6MWT demonstrated by a Spearman Rho correlation of 0.69 (P<0.001).  
Our data also demonstrate that none of the different methods used to detect a practice effect 
showed indications of such an effect. An important implication is that a practice walk is not required and 
that one single test provides sufficiently accurate information. Adequacy of one single test has relevant 
research and clinical consequences since repeated tests are often difficult to implement in clinical trials 
and are less feasible and not cost-effective within busy clinic settings. Also of clinical relevance, since 
only 9.1% was either not eligible or not motivated, the 2MWT can be used to assess and evaluate the 
functional exercise capacity of the vast majority of patients. The 2MWT does not require any technical 
equipment nor extensive training, and therefore can be used on a large scale in low income and/or busy 
settings.  
When using the 2MWT, interpreting change scores and identifying clinically significant changes 
should be an explicit focus. Clinicians are encouraged to understand how changes in scores translate 
into clinical relevance. The MDC95 provides meaningful criteria for assessing changes. Our data show 
that an improvement of 22 meters for men and 21 meters for women on the 2MWT implies that changes 
greater than these distances are necessary to be 95% certain that the changes are not due to 
measurement error or patient variability.  
An important observation of the current study was that leg pain following the test was associated 
with an impaired functional exercise capacity. The finding that musculoskeletal pain is a negatively 
associated with the functional exercise capacity of persons with psychosis is important. Previous 
research, largely among high income countries, has demonstrated that self-report clinical pain affects a 
third of people with schizophrenia (Stubbs et al., 2014). However, experimental pain induction studies 
have found that pain threshold and tolerance is increased in people with schizophrenia compared to 
matched controls (Stubbs et al., 2015).  From our data, it was not possible to determine to which extent 
the comorbid pain has an exact impact on activities of daily life. The present study is the first to show 
that in particular leg pain following activities is associated with a lower functional exercise capacity. 
Therefore, assessment of clinical pain should also become a standard practice when assessing 
performance of daily life activities. Future research should explore how this can be done at low cost and 
within a minimum amount of time. 
It was also observed that the time captured from the SIMPAQ sedentary, SIMPAQ exercise, 
SIMPAQ incidental physical activity measures are associated with the 2MWT performance. Previous 
research has shown that people with psychosis are more sedentary and less physically active than 
matched controls from the general population (Stubbs et al., 2016b; Stubbs et al., 2016c) and that 
physical inactivity (i.e. not meeting physical activity recommendations) is associated with mental and 
physical co-morbidity (Stubbs et al., 2016; Vancampfort et al., 2016), also in people with psychosis in 
Uganda (Vancampfort et al., 2017). The observed associations provide preliminary evidence for the 
importance of considering both, sedentary and physical activity behavior of people with psychosis when 
trying to improve their functional exercise capacity. Not only structured physical activity, i.e. exercise 
should be considered, but also incidental physical activity during daily life. However, our findings should 
be confirmed in longitudinal and intervention studies.  
The reason why BSI-18 depression, anxiety and somatization scores were not associated with 
the 2MWT scores may be owing to the fact that only outpatients who are at least partially recovered 
were included. This is reflected in the relatively low BSI-18 scores. Future research should however 
explore to what extent psychotic or other schizophrenia symptoms interfere with the 2MWT 
performance. Previous research in people with schizophrenia demonstrated that the distance achieved 
on the 6MWT was significantly related to the global assessment of functioning score, to negative 
symptoms, depressive symptoms, cognitive symptoms, the body mass index, smoking behavior, and 
dose of antipsychotic medication (Vancampfort et al., 2012b). 
Data from the present study should be interpreted in the light of some limitations. First, the 
internal validity of the current study could have been improved by adding an age- and gender matched 
control group. Future research comparing 2MWT scores in people with psychosis with an age- and sex-
matched healthy control group could provide a valuable point of reference. Second, we only included 
outpatients and no inpatients and this from the only national referral center of Uganda. This questions 
the generalizability of the findings. In the regional referral centers, mental health facilities and care are 
much less developed. However, the sample size was adequately powered and calculated a-priori. Third, 
our data are cross-sectional and cannot establish cause and effect. Future prospective studies should 
better disentangle the impact of for example musculoskeletal pain on the functional exercise capacity. 
Such studies should also explore the extent to which people with psychosis are more or less responsive 
to behavioural, pharmacological, and non-pharmacological treatments for chronic pain. Further, 
strategies to encourage people with psychosis to become more physically active and that do not 
exacerbate pain are likely to be key in improving the functional outcome of these patients. Finally, the 
majority of the patients were treated with first-generation antipsychotics which are known to have 
extrapyramidal adverse effects (Zhang et al., 2013). It remains to be explored to what extent these side-
effects had an effect on the 2MWT performance.  
In conclusion, the 2MWT is a reliable, valid and clinically feasible tool for evaluating the 
functional exercise capacity in outpatients with psychosis. Clinicians should take into account 
musculoskeletal symptoms and previous physical activity behaviour when performing physical fitness 
tests in this population. In daily clinical practice, no practice tests are needed. Improvements of 22 
meters for men and 21 meters for women will indicate clinically important changes behind measurement 
error or patient variability. 
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Table 1. Psychotropic medication use in Ugandan outpatients with psychosis (n=50) 
Type Number (%) 
Mono-pharmacotherapy 36 (72%) 
Poly-pharmacotherapy 14 (28%) 
First generation antipsychotics  
     Chlorpromazine 9 (18%) 
     Haloperidol 6 (12%) 
     Fluphenazine 6 (12%) 
     Zuclopentixol 3 (6%) 
    Trifluoperazine 2 (4%) 
Second generation antipsychotics  
    Olanzapine 6 (12%) 
    Risperidone 3 (6%) 
     Quetiapine 1 (2%) 
Antidepressants  
     Fluoxetine 5 (10%) 
Mood stabilizers  
     Carbamazepine 6 (12%) 
     Sodium valproate 1 (2%) 
     Lamotrigine 1 (2%) 
Other  









Table 2. Spearman Rho or Pearson correlations with the second 2MWT performance in outpatients 
with psychosis (n=50) 
Variables mean±SD or median (IQR) r with 2MWT P 
Age (years) 33.5 (14.3) -0.17 0.25 
Body mass index 21.9±1.8 -0.01 0.95 
SIMPAQ sedentary time (hr/day) 11.0 (5.0) -0.57 <0.001* 
SIMPAQ walking (min/day) 0.0 (5.5) 0.31 0.024* 
SIMPAQ exercise (min/day) 0.0 (0.0) 0.47 0.001* 
SIMPAQ incidental PA (min/day) 30.0 (21.2) 0.40 0.004* 
BSI depression 11.5 (7.5) -0.25 0.08 
BSI anxiety 10.0 (5.0) -0.11 0.44 
BSI somatization 10.0 (5.0) -0.22 0.12 
*Significant when P<0.05; SD = standard deviation IQR = interquartile range, 2MWT = 2 minute walk 

















Table 3. Backward linear regression analysis with the distance walked on the 2 minute walk test as the dependent variable in people with psychosis (n=50) 
°Only significant correlates were included in the model (i.e. SIMPAQ sedentary, SIMPAQ walking, SIMPAQ exercise, SIMPAQ incidental physical activity, 
gender, presence of locomotor pain before the test and leg pain following the test), *significant when p<0.05, B=unstandardized coefficient, SE= standard error, 




Variables° B SE β t P* 
(Constant) 181.1 16.7 / 10.9 <0.001* 
SIMPAQ sedentary -5.0 1.3 -0.4 -3.7 0.001* 
SIMPAQ exercise 0.7 0.3 0.2 2.2 0.035* 
SIMPAQ incidental 0.4 0.1 0.3 2.9 0.005* 
Leg pain post-test -15.2 8.4 -0.2 -1.9 0.007* 
